Results 1 to 10 of about 101,978 (115)
Antiplatelet resistance in stroke [PDF]
Expert Review of Neurotherapeutics, 2011 Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known, estimates about the two most widely used antiplatelet agents - aspirin and clopidogrel - suggest that the resistance rate is high, irrespective of the definition used and parameters measured. Inadequate antiplatelet responsiveness correlates with an increased risk
Mehmet Akif Topcuoglu +2 more
exaly +3 more sources
British Journal of Pharmacology, 2006 British Journal of Pharmacology (2006) 147, S241–S251.
Gustav, Born, Carlo, Patrono
openaire +2 more sources
British Journal of Haematology, 2008 SummaryPlatelets play a major role in thromboembolic diseases, and so antiplatelet therapy remains crucial in treatment and prophylaxis. Upon vascular injury, platelets rapidly adhere to the exposed subendothelial matrix, after which they become activated, resulting in the recruitment of additional platelets from the circulation to eventually form a ...
Simon F, De Meyer +4 more
openaire +2 more sources
Journal of The Arab Society for Medical Research, 2023 Platelets play a major role in normal hemostatic and thrombotic processes. Aggregation of platelets presents the key pathophysiological step in the development of cardiovascular diseases; hence, antiplatelet agents remain crucial in the treatment of cardiovascular diseases. They may target the three principal phases leading to
Asma Haffouz +2 more
openaire +2 more sources
Antiplatelets and Anticoagulants [PDF]
Clinical Cardiology, 2010 AbstractThose of us who see patients with cardiovascular disorders frequently use antiplatelet and anticoagulant agents; the common agents are aspirin, clopidogrel, and warfarin. This editorial is a personal viewpoint about commonly used drugs, not so commonly used drugs, and drugs that are yet to be used clinically. Copyright © 2010 Wiley Periodicals,
openaire +2 more sources
Precision antiplatelet therapy
Research and Practice in Thrombosis and Haemostasis, 2023 A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire +2 more sources
Antiplatelet drug interactions [PDF]
Journal of Internal Medicine, 2010 Abstract. Mackenzie IS, Coughtrie MWH, MacDonald TM, Wei L. (Medicines Monitoring Unit (MEMO); and Centre for Oncology & Molecular Medicine, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School; Dundee, UK). Antiplatelet drug interactions (Review‐Symposium).
Mackenzie, I. S. +3 more
openaire +3 more sources
Antiplatelet therapies in diabetes
Diabetic Medicine, 2020 AbstractCardiovascular complications remain the main cause of mortality and morbidity in diabetes. This is related to advanced vascular pathology in this population, together with an enhanced thrombotic environment. The increased risk in thrombosis is secondary to platelet hyper‐reactivity and increased levels and/or altered activity of coagulation ...
R. C. Sagar, K. M. Naseem, R. A. Ajjan
openaire +3 more sources
Pharmacogenetics of Antiplatelet Therapy
Annual Review of Pharmacology and Toxicology, 2023 Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of ...
Matteo, Castrichini +2 more
openaire +2 more sources